Literature DB >> 3932988

Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism.

G J Macphee, M J Brodie.   

Abstract

Established partial seizures are often refractory to treatment and many patients receive polypharmacy. An attempt was made to improve seizure control with the substitution of carbamazepine (CBZ) for existing treatment in 7 consecutive unremitting cases of partial epilepsy referred by their physicians as 'intractable'. This produced a significant improvement in control of partial (P less than 0.02) and secondary generalized (P less than 0.01) seizures, with 5 patients experiencing a 50% or greater reduction in seizure frequency. A single patient suffered a generalized seizure during the period of changeover. In 3 cases auto-induction of CBZ metabolism resulted in temporary loss of seizure control which was restored by an increase in dose. A policy of planned substitution of CBZ in partial epilepsy previously regarded as intractable may be successful in selected patients. The possible deleterious effect of CBZ auto-induction should be anticipated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932988      PMCID: PMC2418387          DOI: 10.1136/pgmj.61.719.779

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  24 in total

1.  Chronic antiepileptic toxicity: a review.

Authors:  E H Reynolds
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

2.  The efficacy of carbamazepine combinations in epilepsy.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

3.  Carbamazepine for epilepsy. A controlled prospective evaluation.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

4.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

5.  Paradoxical intoxication--a complication of anticonvulsant administration.

Authors:  A S Troupin; L M Ojemann
Journal:  Epilepsia       Date:  1975-12       Impact factor: 5.864

6.  One drug for epilepsy.

Authors:  S D Shorvon; D Chadwick; A W Galbraith; E H Reynolds
Journal:  Br Med J       Date:  1978-02-25

7.  High-dose monotherapy in treatment of intractable seizures.

Authors:  R P Lesser; C E Pippenger; H Lüders; D S Dinner
Journal:  Neurology       Date:  1984-06       Impact factor: 9.910

8.  A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy.

Authors:  N Simonsen; P Z Olsen; V Kühl; M Lund; J Wendelboe
Journal:  Epilepsia       Date:  1976-06       Impact factor: 5.864

9.  Carbamazepine as a single drug in the treatment of epilepsy. A prospective study of serum levels and seizure control.

Authors:  N Callaghan; M O'Callaghan; B Duggan; M Feely
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-10       Impact factor: 10.154

10.  Carbamazepine--a double-blind comparison with phenytoin.

Authors:  A Troupin; L M Ojemann; L Halpern; C Dodrill; R Wilkus; P Friel; P Feigl
Journal:  Neurology       Date:  1977-06       Impact factor: 9.910

View more
  10 in total

1.  Carbamazepine neurotoxicity precipitated by diltiazem.

Authors:  M J Brodie; G J MacPhee
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-03

Review 2.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

3.  Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.

Authors:  J G Larkin; P J McKee; G Forrest; G H Beastall; B K Park; J I Lowrie; P Lloyd; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

4.  Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients.

Authors:  J G Larkin; P J McKee; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

5.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

8.  Controlled evaluation of a supplementary dose of carbamazepine on psychomotor function in epileptic patients.

Authors:  G J Macphee; E M McPhail; E Butler; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Pharmacokinetic optimisation of anticonvulsant therapy.

Authors:  A H Thomson; M J Brodie
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

10.  A double-blind comparison of conventional and controlled-release carbamazepine in healthy subjects.

Authors:  J G Larkin; A McLellan; A Munday; M Sutherland; E Butler; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.